$2.55
+0.13 (+5.37%)
Open$2.53
Previous Close$2.42
Day High$2.56
Day Low$2.48
52W High$8.54
52W Low$1.99
Volume—
Avg Volume207.6K
Market Cap117.84M
P/E Ratio—
EPS$-0.88
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+110.6% upside
Current
$2.55
$2.55
Target
$5.37
$5.37
$3.28
$5.37 avg
$6.50
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.6K | 59.48M | 62.40M |
| Net Income | -43,209,257 | -10,809,084 | -13,759,336 |
| Profit Margin | -373,362.5% | -18.2% | -22.1% |
| EBITDA | -44,979,122 | -13,281,170 | -15,040,886 |
| Free Cash Flow | — | -10,468,769 | -13,384,851 |
| Rev Growth | — | +6.2% | +12.2% |
| Debt/Equity | — | 0.58 | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |